Small leucine-rich proteoglycans: Multifunctional signaling effectors

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 185-196

  Merline, Rosetta ^a   Nastase, Madalina V ^a   Iozzo, Renato V ^b   Schaefer, Liliana ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877715193     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (87)

1. Amenta, A. R., Yilmaz, A., Bogdanovich, S., et al. (2011). Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A 108, 762-767.
2. Ameye, L., Aria, D., Jepsen, K., Oldberg, A., Xu, T., and Young, M. F. (2002). Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 16, 673-680.
3. Ameye, L., and Young, M. F. (2002). Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 12, 107R-116R.
4. Assheton, D. C., Guerin, E. P., Sheridan, C. M., Bishop, P. N., and Hiscott, P. S. (2007). Neoplastic transformation of ciliary body epithelium is associated with loss of opticin expression. Br J Ophthalmol 91, 230-232.
5. Babelova, A., Moreth, K., Tsalastra-Greul, W., et al. (2009). Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 284, 24035-24048.
6. Bereczki, E., and Santha, M. (2008). The role of biglycan in the heart. Connect Tissue Res 49, 129-132.
7. Bi, Y., Ehirchiou, D., Kilts, T. M., et al. (2007). Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 13, 1219-1227.
8. Bishop, P. N. (2000). Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res 19, 323-344.
9. Bishop, P. N., Takanosu, M., Le Goff, M., and Mayne, R. (2002). The role of the posterior ciliary body in the biosynthesis of vitreous humour. Eye (Lond) 16, 454-460.
10. Border, W. A., Noble, N. A., Yamamoto, T., et al. (1992). Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360, 361-364.
11. Bouhenni, R. A., Al Shahwan, S., Morales, J., et al. (2011). Identification of differentially expressed proteins in the aqueous humor of primary congenital glaucoma. Exp Eye Res 92, 67-75.
12. Brandan, E., Cabello-Verrugio, C., and Vial, C. (2008). Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 27, 700-708.
13. Brezillon, S., Zeltz, C., Schneider, L., et al. (2009). Lumican inhibits B16F1 melanoma cell lung metastasis. J Physiol Pharmacol 60 (Suppl. 4), 15-22.
14. Buraschi, S., Pal, N., Tyler-Rubinstein, N., Owens, R. T., Neill, T., and Iozzo, R. V. (2010). Decorin antagonizes Met receptor activity and down-regulates beta-catenin and Myc levels. J Biol Chem 285, 42075-42085.
15. Carlson, E. C., Lin, M., Liu, C. Y., Kao, W. W., Perez, V. L., and Pearlman, E. (2007). Keratocan and lumican regulate neutrophil infiltration and corneal clarity in lipopolysaccharide-induced keratitis by direct interaction with CXCL1. J Biol Chem 282, 35502-35509.
16. Chakravarti, S., Paul, J., Roberts, L., Chervoneva, I., Oldberg, A., and Birk, D. E. (2003). Ocular and scleral alterations in gene-targeted lumican-fibromodulin double-null mice. Invest Ophthalmol Vis Sci 44, 2422-2432.
17. Chakravarti, S., Petroll, W. M., Hassell, J. R., et al. (2000). Corneal opacity in lumican-null mice: defects in collagen fibril structure and packing in the posterior stroma. Invest Ophthalmol Vis Sci 41, 3365-3373.
18. Chen, X. D., Shi, S., Xu, T., Robey, P. G., and Young, M. F. (2002). Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J Bone Miner Res 17, 331-340.
19. Csont, T., Gorbe, A., Bereczki, E., et al. (2010). Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: role of nitric oxide. J Mol Cell Cardiol 48, 649-652.
20. Csordas, G., Santra, M., Reed, C. C., et al. (2000). Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275, 32879-32887.
21. Danielson, K. G., Baribault, H., Holmes, D. F., Graham, H., Kadler, K. E., and Iozzo, R. V. (1997). Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136, 729-743.
22. De Luca, A., Santra, M., Baldi, A., Giordano, A., and Iozzo, R. V. (1996). Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271, 18961-18965.
23. Derbali, H., Bosse, Y., Cote, N., et al. (2010). Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol 176, 2638-2645.
24. D'Onofrio, M. F., Brezillon, S., Baranek, T., et al. (2008). Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem Biophys Res Commun 365, 266-272.
25. Embree, M. C., Kilts, T. M., Ono, M., et al. (2010). Biglycan and fibromodulin have essential roles in regulating chondrogenesis and extracellular matrix turnover in temporomandibular joint osteoarthritis. Am J Pathol 176, 812-826.
26. Goldoni, S., Humphries, A., Nyström, A., et al. (2009). Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185, 743-754.
27. Goldoni, S., and Iozzo, R. V. (2008). Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123, 2473-2479.
28. Hassell, J. R., and Birk, D. E. (2010). The molecular basis of corneal transparency. Exp Eye Res 91, 326-335.
29. Hayashi, Y., Call, M. K., Chikama, T., et al. (2010). Lumican is required for neutrophil extravasation following corneal injury and wound healing. J Cell Sci 123, 2987-2995.
30. Heegaard, A. M., Corsi, A., Danielsen, C. C., et al. (2007). Biglycan deficiency causes spontaneous aortic dissection and rupture in mice. Circulation 115, 2731-2738.
31. Hildebrand, A., Romaris, M., Rasmussen, L. M., et al. (1994). Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302 (Pt 2), 527-534.
32. Hu, Y., Sun, H., Owens, R. T., et al. (2009). Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 1 1, 1042-1053.
33. Inkson, C. A., Ono, M., Bi, Y., Kuznetsov, S. A., Fisher, L. W., and Young, M. F. (2009). The potential functional interaction of biglycan and WISP-1 in controlling differentiation and proliferation of osteogenic cells. Cells Tissues Organs 189, 153-157.
34. Iozzo, R. V., Moscatello, D. K., McQuillan, D. J., and Eichstetter, I. (1999). Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274, 4489-4492.
35. Iozzo, R. V., and Sanderson, R. D. (2011). Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 1013-1031.
36. Iozzo, R. V., and Schaefer, L. (2010). Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864-3875.
37. Johnson, H. J., Rosenberg, L., Choi, H. U., Garza, S., Hook, M., and Neame, P. J. (1997). Characterization of epiphycan, a small proteoglycan with a leucine-rich repeat core protein. J Biol Chem 272, 18709-18717.
38. Johnson, J., Shinomura, T., Eberspaecher, H., Pinero, G., Decrombrugghe, B., and Hook, M. (1999). Expression and localization of PG-Lb/epiphycan during mouse development. Dev Dyn 216, 499-510.
39. Knudson, C. B., and Knudson, W. (2001). Cartilage proteoglycans. Semin Cell Dev Biol 12, 69-78.
40. Kolb, M., Margetts, P. J., Sime, P. J., and Gauldie, J. (2001). Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 280, L1327-1334.
41. Lam, V., Takechi, R., Pallebage-Gamarallage, M. M., Galloway, S., and Mamo, J. C. (2011). Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer's disease. Neurosci Lett 492, 160-164.
42. Lee, S., Bowrin, K., Hamad, A. R., and Chakravarti, S. (2009). Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to beta2 integrin. J Biol Chem 284, 23662-23669.
43. Li, Y., Aoki, T., Mori, Y., et al. (2004). Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 64, 7058-7064.
44. Little, P. J., Osman, N., and O'Brien, K. D. (2008). Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 19, 448-454.
45. Lohr, K., Sardana, H., Lee, S., et al. (2011). Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis. Inflamm Bowel Dis 18 (1), 143-151.
46. Majava, M., Bishop, P. N., Hagg, P., et al. (2007). Novel mutations in the small leucine-rich repeat protein/proteoglycan (SLRP) genes in high myopia. Hum Mutat 28, 336-344.
47. Mayr, C., Bund, D., Schlee, M., et al. (2005). Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 105, 1566-1573.
48. Melchior-Becker, A., Dai, G., Ding, Z., et al. (2011). Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J Biol Chem 286, 17365-17375.
49. Merline, R., Lazaroski, S., Babelova, A., et al. (2009). Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 60 (Suppl. 4), 5-13.
50. Merline, R., Moreth, K., Beckmann, J., et al. (2011). Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal, 4, ra75.
51. Mikaelsson, E., Danesh-Manesh, A. H., Luppert, A., et al. (2005). Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood 105, 4828-4835.
52. Monfort, J., Tardif, G., Roughley, P., et al. (2008). Identification of opticin, a member of the small leucine-rich repeat proteoglycan family, in human articular tissues: a novel target for MMP-13 in osteoarthritis. Osteoarthritis Cartilage 16, 749-755.
53. Moreth, K., Brodbeck, R., Babelova, A., et al. (2010). The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 120, 4251-4272.
54. Moreth, K., Iozzo, R. V., and Schaefer, L. (2012). Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 11, 2084-2091.
55. Moscatello, D. K., Santra, M., Mann, D. M., McQuillan, D. J., Wong, A. J., and Iozzo, R. V. (1998). Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101, 406-412.
56. Nuka, S., Zhou, W., Henry, S. P., et al. (2010). Phenotypic characterization of epiphycandeficient and epiphycan/biglycan double-deficient mice. Osteoarthritis Cartilage 18, 88-96.
57. Oldberg, A., Kalamajski, S., Salnikov, A. V., et al. (2007). Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci U S A 104, 13966-13971.
58. Pattwell, D. M., Sheridan, C. M., Le Goff, M., Bishop, P. N., and Hiscott, P. (2010). Localisation of opticin in human proliferative retinal disease. Exp Eye Res 90, 461-464.
59. Ramesh, S., Bonshek, R. E., and Bishop, P. N. (2004). Immunolocalisation of opticin in the human eye. Br J Ophthalmol 88, 697-702.
60. Reardon, A. J., Le Goff, M., Briggs, M. D., et al. (2000). Identification in vitreous and molecular cloning of opticin, a novel member of the family of leucine-rich repeat proteins of the extracellular matrix. J Biol Chem 275, 2123-2129.
61. Reed, C. C., and Iozzo, R. V. (2002). The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19, 249-255.
62. Reed, C. C., Waterhouse, A., Kirby, S., et al. (2005). Decorin prevents metastatic spreading of breast cancer. Oncogene 24, 1104-1110.
63. Roughley, P. J. (2006). The structure and function of cartilage proteoglycans. Eur Cell Mater 12, 92-101.
64. Santra, M., Reed, C. C., and Iozzo, R. V. (2002). Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J Biol Chem 277, 35671-35681.
65. Schaefer, L. (2011). Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol 22, 1200-1207.
66. Schaefer, L., Babelova, A., Kiss, E., et al. (2005). The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115, 2223-2233.
67. Schaefer, L., and Iozzo, R. V. (2008). Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 283, 21305-21309.
68. Schaefer, L., and Iozzo, R. V. (2012). Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 22, 56-57.
69. Schaefer, L., Macakova, K., Raslik, I., et al. (2002). Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 160, 1181-1191.
70. Schaefer, L., Tsalastra, W., Babelova, A., et al. (2007). Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol 170, 301-315.
71. Schonherr, E., Sunderkotter, C., Iozzo, R. V., and Schaefer, L. (2005). Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 280, 15767-15772.
72. Seidler, D. G., Goldoni, S., Agnew, C., et al. (2006). Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281, 26408-26418.
73. Sjoberg, A. P., Manderson, G. A., Morgelin, M., Day, A. J., Heinegard, D., and Blom, A. M. (2009). Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 46, 830-839.
74. Soo, C., Hu, F. Y., Zhang, X., et al. (2000). Differential expression of fibromodulin, a transforming growth factor-beta modulator, in fetal skin development and scarless repair. Am J Pathol 157, 423-433.
75. Svensson, L., Aszodi, A., Reinholt, F. P., Fassler, R., Heinegard, D., and Oldberg, A. (1999). Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J Biol Chem 274, 9636-9647.
76. Tralhao, J. G., Schaefer, L., Micegova, M., et al. (2003). In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 17, 464-466.
77. Vial, C., Gutierrez, J., Santander, C., Cabrera, D., and Brandan, E. (2011). Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. J Biol Chem 286, 24242-24252.
78. Vij, N., Roberts, L., Joyce, S., and Chakravarti, S. (2004). Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea. Exp Eye Res 78, 957-971.
79. Vij, N., Roberts, L., Joyce, S., and Chakravarti, S. (2005). Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest Ophthalmol Vis Sci 46, 88-95.
80. Vuillermoz, B., Khoruzhenko, A., D'Onofrio, M. F., et al. (2004). The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296, 294-306.
81. Westermann, D., Mersmann, J., Melchior, A., et al. (2008). Biglycan is required for adaptive remodeling after myocardial infarction. Circulation 117, 1269-1276.
82. Wu, F., Vij, N., Roberts, L., Lopez-Briones, S., Joyce, S., and Chakravarti, S. (2007). A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem 282, 26409-26417.
83. Yamaguchi, Y., Mann, D. M., and Ruoslahti, E. (1990). Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346, 281-284.
84. Ying, S., Shiraishi, A., Kao, C. W., et al. (1997). Characterization and expression of the mouse lumican gene. J Biol Chem 272, 30306-30313.
85. Zeltz, C., Brezillon, S., Kapyla, J., et al. (2010). Lumican inhibits cell migration through alpha2beta1 integrin. Exp Cell Res 316, 2922-2931.
86. Zheng, Z., Nguyen, C., Zhang, X., et al. (2011). Delayed wound closure infibromodulin-deficient mice is associated with increased TGF-beta3 signaling. J Invest Dermatol 131, 769-778.
87. Zhu, J. X., Goldoni, S., Bix, G., et al. (2005). Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem 280, 32468-32479.